Be the first to know and let us send you an email when BDR Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Established in 2002 into API manufacturing, we have a consolidated position in the domestic and global market for the API Business.
In today’s dynamic global pharmaceutical market, we at BDR Pharmaceuticals have carved a niche for ourselves, with our formulations portfolio for specialty medication. Our unique strategy of multi-branding ensures that critical and lifesaving medicines are available at affordable prices with two API and formulation facilities at Gujarat, Uttarakhand and a pellet facility at Hyderabad.
Awards/Accolades/Achievements-
Enjoys Star Export House status, recognized and issued by Ministry of Commerce & Industry.
Recipient of Outstanding Exports Award from Pharmexcil.
DSIR accreditation for BDR Pharma R&D facility and API R&D at Baroda.
BDR is the first generic formulator in the world for many lifesaving molecules.
Mr Dharmesh Shah has been bestowed with “The Hurun India Award 2019 for Industry Achievement in the field of Pharmaceuticals”
Company Milestones -
Established in 2002 as a Merchant Exporter.
Internationally recognized and renowned Merchant Exporter of API and finished products since 2002.
Star Export House status, recognized and issued by Ministry of Commerce & Industry.
API manufacturing facility called Virdev Intermediates in 2006 in Surat, Gujarat
BDR Lifesciences another API manufacturing facility at Vadodara, Gujarat in 2010.
Pellets manufacturing facility located in Hyderabad, Telangana in 2013.
BDR Pharmaceuticals International Pvt Ltd has a dedicated oncology oral manufacturing facility in Vadodara, Gujarat in 2015
DSIR accreditation for BDR Pharma R&D facility and API R&D at Baroda.
First generic formulation manufacturer in life saving critical segments.
Critical segments are:
Oncology
Neurology
Gynaecology
Fifth Generation antibiotics
Achieved 30 % growth since inception in 2003.
In the process of filing Dossiers in a number of international markets for product registration with tech transfer understanding.
· In today’s perspective, BDR is one of the fastest growing companies in India, focusing in two critically vital areas of operations, i.e. 1. Expanding products basket in each therapeutic segment and 2. From a futuristic view, building a world-class and state-of-the-art modern infrastructure qualifying for USA and European accreditations.
· We boast of having already built an in operation, contemporary R & D, F &D spread over an expansive area of 65000 sq ft and capable of undertaking research works in diverse fields. We have an ambitious programme to qualify this modern, state-of-the-art R&D - F&D Centre through USFDA inspection soon and then proceed for filing ANDA from this site.
· BDR is strengthening /diversifying our manufacturing capabilities through building two large production blocks , i.e. 1. for General Lyophilisation, Liquid Injection and Dry Powder and 2. dedicated Oncology unit for Soft Gel, Dry Powder Depot and PFS . Probably, BDR will qualify for the distinction of being the 1st Company in India for having manufacturing areas for Oncology lyophilisation as well as liquid injection under the same roof.
Reputed Indian pharmaceutical companies who are our marketing partners in formulation business :
